产品
编 号：F673695
分子式：C21H25NO4
分子量：355.43
分子式：C21H25NO4
分子量：355.43
产品类型
规格
价格
是否有货
结构图
CAS No: 1245818-17-0
产品详情
生物活性：
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.
体内研究：
Ppc-1 (0-10 mg /kg; Intraperitoneal injection; once a week; for 8 weeks; female ICR mice) treatment suppresses weight gain with no abnormal effects on liver or kidney tissues, and no evidence of tumor formation. Serum fatty acid levels are significantly elevated in mice treated with Ppc-1, while body fat content remained low. After a single administration, Ppc-1 distributes into various tissues of individual animals at low levels. Ppc-1 stimulates adipocytes in culture to release fatty acids, which might explain the elevated serum fatty acids in Ppc-1-treated mice.Animal Model:Female ICR mice
Dosage:0 mg /kg , 0.16 mg /kg, 0.8 mg /kg, 4 mg /kg, and 10 mg /kg
Administration:Intraperitoneal injection; once a week; for 8 weeks
Result:Suppresseed weight gain in animals.
体外研究：
Ppc-1 treatment (0-10 μM; 24 hours; Jurkat cells) significant inhibits IL-2 production in Jurkat cells with an IC50 of 4 μM.Ppc-1 (compound 6) has antiproliferative activities in K562 human leukemia, Hela cervical carcinoma, and 3T3-L1 mouse embryonic fibroblast cells. Ppc-1 shows about 50% inhibition at 15 μM in all cell lines. Ppc-1 inhibits the growth of K562 cells with an EC50 of 13 μM.Using the U937-3xκB-LUC human monocytic cell line, Ppc-1 dose-dependently inhibits the lipopolysaccharide-induced NF-κB activation.
Ppc-1 is a mitochondrial uncoupler. Ppc-1 enhances mitochondrial oxygen consumption without adverse effects on ATP production. Ppc-1 is a cell-permeate interleukin-2 (IL-2) inhibitor. Ppc-1 inhibits the Gram-negative periodontopathogen Porphyromonas gingivalis. Ppc-1 has anti-obesity, antibacterial and anti-inflammatory activities.
体内研究：
Ppc-1 (0-10 mg /kg; Intraperitoneal injection; once a week; for 8 weeks; female ICR mice) treatment suppresses weight gain with no abnormal effects on liver or kidney tissues, and no evidence of tumor formation. Serum fatty acid levels are significantly elevated in mice treated with Ppc-1, while body fat content remained low. After a single administration, Ppc-1 distributes into various tissues of individual animals at low levels. Ppc-1 stimulates adipocytes in culture to release fatty acids, which might explain the elevated serum fatty acids in Ppc-1-treated mice.Animal Model:Female ICR mice
Dosage:0 mg /kg , 0.16 mg /kg, 0.8 mg /kg, 4 mg /kg, and 10 mg /kg
Administration:Intraperitoneal injection; once a week; for 8 weeks
Result:Suppresseed weight gain in animals.
体外研究：
Ppc-1 treatment (0-10 μM; 24 hours; Jurkat cells) significant inhibits IL-2 production in Jurkat cells with an IC50 of 4 μM.Ppc-1 (compound 6) has antiproliferative activities in K562 human leukemia, Hela cervical carcinoma, and 3T3-L1 mouse embryonic fibroblast cells. Ppc-1 shows about 50% inhibition at 15 μM in all cell lines. Ppc-1 inhibits the growth of K562 cells with an EC50 of 13 μM.Using the U937-3xκB-LUC human monocytic cell line, Ppc-1 dose-dependently inhibits the lipopolysaccharide-induced NF-κB activation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备